Live Webinar on January 25: Unlocking RWE’s Potential for HCP Engagement
DATE
January 10, 2024
Munich – Wednesday, January 10th, 2024 – eCOA and EDC software company Climedo is inviting professionals from pharmaceutical companies and CROs to join a free 60-minute webcast with an expert from Merck about “Unlocking RWE’s Potential for HCP Engagement” on January 25.
Real-world evidence (RWE) offers perspectives on the clinical efficacy and cost of treatments, the performance of healthcare systems, highlighting unmet needs and optimal clinical practices in real-world settings. But how can it be leveraged to better understand new oncology mutations and patient characteristics, optimize treatment pathways and improve clinical outcomes?
In the next Climedo Connect webcast on January 25, 2024, Dr. Helene Vioix, Director Global Value Development Oncology at Merck, will present best practices on how to maximize the impact of real-world data to best engage Healthcare Professionals (HCPs) and Key Thought Leaders (KTLs).
The session will address:
- How to engage Key Thought Leaders (KTLs) throughout the feasibility phase for invaluable insights
- How to create novel evidence and gain Health Technology Assessment (HTA) acceptance
- How to leverage KTL support to disseminate results to wider Key Opinion Leader (KOL) groups
- Innovative approaches for enhancing more traditional registries, all while navigating regulatory challenges.
Additionally, attendees will have the opportunity to engage in live surveys, network with peers and ask any questions they may have. Registration is free via this link, and registrants will receive access to the event’s slide deck and recording afterwards. Specific questions and requests may be submitted ahead of the event by reaching out to hello@climedo.de.
Media contact
Catherine Higginson
Marketing & Communications Lead
catherine.higginson@climedo.de
About Climedo
The leading European eCOA system for non-interventional studies, RWE and launch success
Climedo offers an all-in-one eCOA and EDC solution with hybrid capabilities for non-interventional studies and real-world evidence. By using a patient-centric approach and leveraging real-time data insights and visualizations around a study’s current progress, Climedo empowers its clients to better engage with healthcare professionals and other key opinion leaders (KOLs). This boosts awareness, stimulates scientific dialogue and accelerates the launch success of new medical innovations, thus reaching more patients faster. Founded in Munich in 2017, Climedo is a leading trusted partner for pharma, medtech, CROs and academia with over 1.7 million patients enrolled to date. Learn more at www.climedo.com.
